This review discusses the potential of cinnamic acid hybrids in targeting Alzheimer's disease (AD). Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline, with current treatments primarily focusing on acetylcholinesterase (AChE) inhibition, offering only temporary relief. Promising alternatives include butyrylcholinesterase (BuChE) inhibitors, multi-target ligands (MTDLs), and compounds targeting oxidative stress and inflammation. Cinnamic acid derivatives, known for their neuroprotective properties, show potential when combined with established AD agents, demonstrating improved efficacy. They are being positioned as potential AD therapeutic leads due to their ability to inhibit Aβ accumulation and provide neuroprotection. The article highlights the potential of cinnamic acid as a versatile structure that can be combined with various active groups to combat AD. Compounds with a methoxy substitution at the para-position of cinnamic acid display increased efficacy, while electron-withdrawing groups are generally more effective. The effect of molecular volume is worth further investigation. The review summarizes recent advances in the use of cinnamic acid derivatives synthesized by hybridization with established bioactive moieties for AD treatment. It analyzes the results of these studies and highlights the multifaceted activities of these compounds as multi-target agents. The review discusses various cinnamic acid hybrids, including tacrine derivatives, isoquinoline and quinoline derivatives, benzylpiperidine derivatives, β-carboline analogs, tryptamine derivatives, and rivastigmine derivatives. These compounds show promise in inhibiting AChE and BuChE, reducing Aβ accumulation, and exhibiting antioxidant and neuroprotective properties. The study emphasizes the importance of further research into cinnamic acid hybrids for the prevention and treatment of Alzheimer's disease.This review discusses the potential of cinnamic acid hybrids in targeting Alzheimer's disease (AD). Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline, with current treatments primarily focusing on acetylcholinesterase (AChE) inhibition, offering only temporary relief. Promising alternatives include butyrylcholinesterase (BuChE) inhibitors, multi-target ligands (MTDLs), and compounds targeting oxidative stress and inflammation. Cinnamic acid derivatives, known for their neuroprotective properties, show potential when combined with established AD agents, demonstrating improved efficacy. They are being positioned as potential AD therapeutic leads due to their ability to inhibit Aβ accumulation and provide neuroprotection. The article highlights the potential of cinnamic acid as a versatile structure that can be combined with various active groups to combat AD. Compounds with a methoxy substitution at the para-position of cinnamic acid display increased efficacy, while electron-withdrawing groups are generally more effective. The effect of molecular volume is worth further investigation. The review summarizes recent advances in the use of cinnamic acid derivatives synthesized by hybridization with established bioactive moieties for AD treatment. It analyzes the results of these studies and highlights the multifaceted activities of these compounds as multi-target agents. The review discusses various cinnamic acid hybrids, including tacrine derivatives, isoquinoline and quinoline derivatives, benzylpiperidine derivatives, β-carboline analogs, tryptamine derivatives, and rivastigmine derivatives. These compounds show promise in inhibiting AChE and BuChE, reducing Aβ accumulation, and exhibiting antioxidant and neuroprotective properties. The study emphasizes the importance of further research into cinnamic acid hybrids for the prevention and treatment of Alzheimer's disease.